Novel zolpidem formulations

Drugs of Today

Volumn 45, Issue 5, 2009, Pages 395-400

  Owen, Richard T ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EDLUAR; ESCITALOPRAM; INTERMEZZO; OX 22; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOLPIMIST;

AEROSOL; AREA UNDER THE CURVE; BEDTIME DOSAGE; BIOEQUIVALENCE; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; FATIGUE; FOOD; FOOD DRUG INTERACTION; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; LOZENGE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; REVIEW; SLEEP RELATED EATING BEHAVIOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNITED STATES;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; AEROSOLS; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; HUMANS; HYPNOTICS AND SEDATIVES; PYRIDINES;

EID: 69249191575     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.5.1377599     Document Type: Review

References (28)

1. http://en.sanofi-aventis.com/products-presence/medicines-vaccines/cns/ stilnox-ambien-myslee/stilnox-ambien-myslee.asp
2. Rosenberg, R.P. Sleep maintenance insomnia: Strengths and weaknesses of current pharmacological therapies. Ann Clin Psychiatry 2006, 18(1): 49-56.
3. Scharf,M.B., Roth, T., Vogel, G.W., Walsh, J.K. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994, 55(5): 192-199 (Pubitemid 24184828)
4. Lahmeyer, h., Wilcok, C.S., Kann, J., Leppik, I. Subjective efficacy of zolpidem in outpatients with chronic insomnia: A double-blind comparison with placebo. Clin Drug Invest 1997, 13(3): 134-144
5. Owen, R.T. Extended release zolpidem: Efficacy and tolerability profile. Drugs Today 2006, 42(11): 721-727
6. www.ambiencr.com (accessed 3 February 2009).
7. Partinen, M., Hirvonen, K., Hublin, C., Halvaara, M., Hilturen, H. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med 2003, 4(6); 553-561 (Pubitemid 38145658)
8. Verster, J.C., Volkerts, E.R., Schreuder, A.H. et al. Residual effects of middle of the night administration of zaleplon and zolpidem on driving ability, memory functions and psychomotor performance. J Clin Psychopharmacol 2002, 22(6): 576-583
9. Erman, M., Krystal, A., Zammit, G., Soubrane, C., Roth, T. Zolpidem extended-release 12.5 mg taken for 24 weeks 'as needed' up to nights/week improves subjective measures of therapeutic global impression, sleep onset and sleep maintenance in patients with chronic insomnia. Int J Neuropsychopharmacol 2006, 9 (Suppl. 1): S256: Abst P.03.106
10. Krystal, A.D., Erman, M., Zammit, G.K., Soubrane, C., Roth, T. Long-term efficacy and safety of zolpidem extended-release 12.5 mg administered 3 to 7 nights/week for 24 weeks in patients with chronic primary insomnia: A 6-month randomized, double-blind, placebo-controlled, parallel group, multicenter study. Sleep 2008, 31(1): 79-90.
11. Erman, M., Guiraud, A., Joish, V.N., Lerner, D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep 2008, 31(10): 1371-1378
12. Walsh, J.K., Soubrane, C., Roth, T. Efficacy and safety of zolpidem extended-release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008, 16(1): 44-57.
13. Asnis, G., Ram, S., Bruce, L. et al. Improved insomnia symptoms, quality of life and daily functioning in patients with comorbid generalized anxiety disorder and insomnia following concomitant zolpidem extended release 12.5 mg and escitalopram treatment. Annu Meet Am Coll Clin Pharm (ACCP) (14-17 Oct, Denver) 2007, Abst 143.
14. Fava, M., Asnis, G., Shrivastava, R. et al. Improved insomnia symptoms and daily functioning in patients with comorbid major depressive disorder and insomnia following zolpidem extended-release 12.5 mg and escitaloprom treatment. Sleep 2008, 31(Abst Suppl): Abst 0984.
15. Sheehan, D., Asnis, G., Shrivastava, R. et al. Zolpidem extended-release 12.5 mg improves sleep and next-day functioning in patients with comorbid insomnia and generalized anxiety disorder. 161st Annu Meet Am Psychiatric Assoc (APA) (May 3-7, Washington) 2008, Abst NR6-089.
16. Fava, M., Asnis, G., Shrivastava,R. et al. Zolpidem extended-release, co-administered with escitolopram, improves insomnia in patients with comorbid insomnia and major depressive disorder. 161st Annu Meet Am Psychiatric Assoc (APA) (May 3-7, Washington) 2008, Abst NR6-088.
17. Chiang, A. and Krystal, A. Report of two cases where sleep related eating behaviour occurred with the extended release formulation but not the immediate release formulation of a sedative hypnotic. J Clin Sleep Med 2008, 4(2); 155-156 (Pubitemid 352038656)
18. Roth, T., Mayleben, T., Corser, B.C., Singh, N.N. Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol Clin Exp 2008, 23(1):13-20. (Pubitemid 351166064)
19. Krystal, A.D., Kalin, R., Maguire, Y., Singh, N., Mayton, M. A pharmacokinetic study of the coadministration of a high fat meal with a low-dose, sublingual formulation of zolpidem tartrate. Sleep 2008, 31(Abst Suppl): Abst 0105.
20. Roth, T., Krystal, A.D., Maguire, Y., Singh, N., Maytom, M. Pharmacokinetics of the sublingual zolpidem tartrate 3.5 mg lozenge compared to the oral zolpidem tartrate 10 mg tablet. Sleep 2008, 31(Abst Suppl): Abst 0714.
21. Krystal, A.D., Scharf, M.B., Mordy, C., Singh, N., Maytom, M. Pharmacokinetics of a low-dose, sublingual formulation of zolpidem tartrate in elderly subjects. Sleep 2008, 31(Abst Suppl): Abst 0713.
22. Hull, S., Roth, T., Scharf, M. et al. Dose-response effects of sublingual transmucosal zolpidem 3.5 mg and 175 mg in middle of the night insomnia. Sleep 2007, 30(Abst Suppl): Abst 0707.
23. Staner, L., Muscat, N., Cornette, F. et al. Sublingual zolpidem compared to oral zolpidem in the post-nap model of insomnia. Sleep 2006, 29(Abst Suppl): Abst 0748.
24. Staner, L., Wrikkson, M., Cornette, F. et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: A polysomnographic study. Sleep Med 2009, 10(6): 616-620
25. Novadel announces positive data from two studies comparing zolpidem oral spray to Ambien® Tablets. www.integratir.com/newsrelease.asp?news= 2130983049&ticker=NVD&lang=EN (accessed 3 February 2009).
26. Corporate Slide presentation by Novadel. http://www.novadel.com/pdf/ 20081222Corporate%20Presentation.pdf (accessed 3 February 2009).
27. Dilone, E., Arumugam, U., Bergsrrom, D.H. et al. Evaluation of the effect of the route of administration on the human metabolite pattern of zolpidem: ZolpiMist oral spray compared to Ambien® Tablets. AAPS Journal 2008, 10(S2). http://www.aapsj.org/abstracts/AM-2008/AAPS2008-001124.PDF (accessed 3 February 2009)
28. Zolpimist US Prescribing information. http://www.fda.gov/cder/foi/label/ 2008/022196lbl.pdf (accessed 3 February 2009).